- Home
- RYN vs AKRO Comparison
RYN vs AKRO Comparison
Compare RYN & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYN
- AKRO
- Stock Information
- Founded
- RYN 1926
- AKRO 2017
- Country
- RYN United States
- AKRO United States
- Employees
- RYN N/A
- AKRO N/A
- Industry
- RYN Real Estate Investment Trusts
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- RYN Real Estate
- AKRO Health Care
- Exchange
- RYN Nasdaq
- AKRO Nasdaq
- Market Cap
- RYN 3.5B
- AKRO 3.7B
- IPO Year
- RYN N/A
- AKRO 2019
- Fundamental
- Price
- RYN $21.78
- AKRO $54.29
- Analyst Decision
- RYN Hold
- AKRO Buy
- Analyst Count
- RYN 4
- AKRO 10
- Target Price
- RYN $27.25
- AKRO $73.56
- AVG Volume (30 Days)
- RYN 1.6M
- AKRO 1.6M
- Earning Date
- RYN 11-05-2025
- AKRO 11-07-2025
- Dividend Yield
- RYN 13.06%
- AKRO N/A
- EPS Growth
- RYN 373.92
- AKRO N/A
- EPS
- RYN 5.07
- AKRO N/A
- Revenue
- RYN $1,293,427,000.00
- AKRO N/A
- Revenue This Year
- RYN N/A
- AKRO N/A
- Revenue Next Year
- RYN $3.00
- AKRO N/A
- P/E Ratio
- RYN $4.37
- AKRO N/A
- Revenue Growth
- RYN 47.70
- AKRO N/A
- 52 Week Low
- RYN $21.23
- AKRO $21.34
- 52 Week High
- RYN $32.74
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- RYN 31.87
- AKRO 68.62
- Support Level
- RYN $21.97
- AKRO $53.90
- Resistance Level
- RYN $23.33
- AKRO $54.37
- Average True Range (ATR)
- RYN 0.57
- AKRO 0.20
- MACD
- RYN 0.03
- AKRO -0.23
- Stochastic Oscillator
- RYN 23.53
- AKRO 90.40
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.